乳腺癌抗肿瘤血管治疗的临床进展

doi:10.11904/j.issn.1002-3070.2019.05.015

摘要/Abstract

摘要： 血管生成是肿瘤发生发展的关键条件之一,抗血管生成药物可阻断血管生成,被认为是治疗各种癌症,特别是晚期癌症的一个重要的突破。抗血管生成药物在晚期胃癌、结直肠癌、前列腺癌及肝癌患者联合化疗中显示出较好的疗效。然而,在乳腺癌中,研究却显示了矛盾的结果,引起了关于这种药物价值的争论。本文回顾了乳腺癌抗血管生成治疗选择的证据,并讨论了限制抗血管生成药物有效性的可能因素,并提出了关于乳腺癌未来治疗方法研究的建议。

关键词: 抗血管生成药物, 乳腺癌, 贝伐单抗, 预测生物标记物

Abstract: Angiogenesis is one of key conditions for tumorigenesis.Anti-angiogenic drugs block angiogenesis and are considered to be an important breakthrough in the treatment of various types of cancer,especially advanced cancer.Anti-angiogenic drugs have shown good efficacy in combination chemotherapy in patients with advanced gastric cancer,colorectal cancer,prostate cancer and advanced liver cancer.However,many studies have shown contradictory results in breast cancer,causing controversy about the value of this drug.In this article,we review the evidence for anti-angiogenic therapy options for breast cancer,discuss possible factors limiting the effectiveness of anti-angiogenic drugs,and suggest future research on these therapies for the treatment of breast cancer.

Key words: Anti-angiogenic drugs, Breast cancer, Bevacizumab, Predictive biomarker

中图分类号:

R737.9

李磊 , 张清媛. 乳腺癌抗肿瘤血管治疗的临床进展[J]. 实用肿瘤学杂志, 2019, 33(5): 461-465.

LI Lei, ZHANG Qingyuan. Clinical progress of anti-tumor vascular therapy for breast cancer[J]. Journal of Practical Oncology, 2019, 33(5): 461-465.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.05.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I5/461

参考文献

1 Fidler IJ,Ellis LM.The implications of angiogenesis for the biology and therapy of cancer metastasis[J].Cell,1994,79(2):185-188.
2 Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357(26):2666-2676.
3 Aparicio-Gallego G,Blanco M,Figueroa A,et al.New insights into molecular mechanisms of sunitinib-associated side effects[J].Mol Cancer Ther,2011,10:2215-2223.
4 Gotink KJ,Verheul HMW.Anti-angiogenic tyrosine kinase inhibitors:what is their mechanism of action?[J].Angiogenesis,2010,13:1-14.
5 Tan AR,Buyse ME,Rastogi P,et al.NSABP FB-6:phase II trial of weekly paclitaxel(WP)and pazopanib following doxorubicin and cyclophosphamide(AC)as neoadjuvant therapy for HER2-negative locally advanced breast cancer(LABC)[J].J Surg Oncol,2012,95(7):530-531.
6 Miller K,O'Neill A,Dang C,et al.Bevacizumab(B)in the adjuvant treatment of breast cancer-first toxicity results from eastern cooperative oncology group trial E5103[J].Cancer Res,2012,72(24):331-337.
7 Palazzo A,Dellapasqua S,Munzone E,et al.Phase II Trial of bevacizumab plus weekly paclitaxel,carboplatin,and metronomic cyclophosphamide with or without trastuzumab and endocrinetherapy as preoperative treatment of inflammatory breastcancer[J].Clin Breast Cancer,2018,18(4):328-335.
8 Dickler MN,Barry WT,Cirrincione CT,et al.Phase III trialevaluating letrozole as first-line endocrine therapy with or without bevacizumab for thetreatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer:CALGB 40503(alliance)[J].J Clin Oncol,2016,34(22):2602-2609.
9 Martín M,Al E.Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer-First efficacy results from the LEA study[J].Cancer Res,2012,72(24):1-7.
10 Sooyoung S,Yoojin N.Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer:a meta-analysis of randomized controlled trials[J].Ther Clin Risk Manage,2018,14:833-847.
11 Miles DW,De Haas SL,Dirix LY,et al.Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for Her2-negative metastatic breast cancer[J].Br J Cancer,2013,108(5):1052-1060.
12 Cutsem EV,Haas SD,Kang YK,et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a biomarker evaluation from the AVAGAST randomized phase III trial[J].J Clin Oncol,2012,30(17):2119-2127.
13 Melanie J,Müller V,Vettorazzi E,et al.Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab:a biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial[J].Clin Oncol,2016,34:1150-1155.
14 Gampenrieder SP,Rinnerthaler G,Hackl H,et al.DNA methylation signatures predicting bevacizumab efficacy in metastatic breast cancer[J].Theranostics,2018,8(8):2278-2288.
15 Desai J,Gurney H,Pavlakis N,et al.Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor:Recommendations for patient management[J].Asia-Pac J Clin Oncol,2010,3(4):167-176.
16 Crown JP,Diéras V,Staroslawska E,et al.Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer[J].J Clin Oncol,2013,31(23):2870.
17 Curigliano G,Pivot X,Cortés J,et al.Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer[J].Breast,2013,22(5):650-656.
18 Yardley DA,Shipley DL,Peacock NW,et al.Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer[J].Breast Cancer Res Treat,2015,152(3):557-567.
19 Elgebaly A,Menshawy A,El Ashal G,et al.Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer:A systematic review and meta-analysis[J].Breast Dis,2016,36(2/3):91-101.
20 Zafrakas M,Papasozomenou P,Emmanouilides C.Sorafenib in breast cancer treatment:A systematic review and overview of clinical trials[J].World J Clin Oncol,2016,7(4):331-336.
21 Chen J,Tian CX,Yu M,et al.Efficacy and safety profile of combining sorafenib with chemotherapy in patients with HER2-negative advanced breast cancer:a meta-analysis[J].J Breast Cancer,2014,17(1):61-68.
22 Zafrakas M,Papasozomenou P,Emmanouilides C.Sorafenib in breast cancer treatment:A systematic review and overview of clinical trials[J].World J Clin Oncol,2016,7(4):331-336.
23 周陈建,赵嫏嬛,胡国新.帕唑帕尼的临床应用和药品不良反应的研究进展[J].药学实践杂志,2016,34(6):497-500.
24 Criscitiello C,Gelao L,Viale G,et al.Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy[J].Expert Opin Invest Drugs,2014,23(5):599-610.
25 Cheng TF,Ou-Yang F,Lapke N,et al.Pazopanib Sensitivity in a patient with Breast cancer and FGFR1 amplification[J].JNCCN,2017,15(12):1456-1459.
26 Casak SJ,Fashoyinaje I,Lemery SJ,et al.FDA Approval summary:ramucirumab for gastric cancer[J].Clin Cancer Res,2015,21(15):3372-3376.
27 Fala L.Cyramza(Ramucirumab)approved for the treatment of advanced gastric cancer and metastatic non-small-cell lung cancer[J].Am Health Drug Benefits,2015,8(Spec Feature):49-53.
28 Mackey JR,Ramosvazquez M,Lipatov O,et al.Primary Results of ROSE/TRIO-12,a aandomized placebo-controlledphase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer[J].J Clin Oncol,2015,33(2):141-148.
29 Schneider BP,Li L,Shen F,et al.Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100[J].Br J Cancer,2014,111(6):1241-1248.
30 Zhang H.Apatinib for molecular targeted therapy in tumor[J].Drug Des Dev Ther,2015,9:6075-6081.
31 Hu X,Zhang J,Xu B,et al.Multicenterphase II study of apatinib,a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple negative breast cancer[J].Int J Cancer,2014,135(8):1961-1969.
32 Hu X,Cao J,Hu W,et al.Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer,2014,14:820.
33 查天麒,卢凯华.阿帕替尼临床应用的研究进展[J].江苏医药,2017,43(13):958-961.

[1]	师镘茹, 鄂明艳. 放疗延迟对乳腺癌不同分子亚型患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 431-435.
[2]	王宇, 乔娟娟, 张磊, 刘四卫 , 杨树才. 类固醇激素在乳腺癌中的作用及对肿瘤干细胞的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 466-470.
[3]	刘尔钰, 杨昊, 梁国华, 赵晏方, 赵文辉. CDK4/6抑制剂联合mTOR抑制剂在乳腺癌中的作用机制[J]. 实用肿瘤学杂志, 2019, 33(5): 476-480.
[4]	安巍巍, 唐雅莉, 赵莲花, 杨悦, 王新玲. 红松松塔提取物多聚苯丙素-多糖复合物诱导人乳腺癌MCF-7细胞凋亡[J]. 实用肿瘤学杂志, 2019, 33(4): 289-293.
[5]	胡琳, 沈佳. GDF-15在预测和监控表柔比星/环磷酰胺-多西他赛-曲妥珠单抗辅助治疗HER-2阳性乳腺癌患者产生心脏毒性中的作用[J]. 实用肿瘤学杂志, 2019, 33(4): 340-345.
[6]	马焱, 何红, 王赛男. 多西他赛解救治疗不同年龄组转移性乳腺癌的临床研究[J]. 实用肿瘤学杂志, 2019, 33(4): 352-356.
[7]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[8]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[9]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[10]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[11]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[12]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[13]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[14]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[15]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.